Salazar Michelle C, Canavan Maureen E, Walters Samantha L, Chilakamarry Sitaram, Ermer Theresa, Blasberg Justin D, Yu James B, Gross Cary P, Boffa Daniel J
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut.
National Clinician Scholars Program, Yale University School of Medicine, New Haven, Connecticut.
JTO Clin Res Rep. 2021 Jan 21;2(3):100143. doi: 10.1016/j.jtocrr.2021.100143. eCollection 2021 Mar.
Patients with early-stage NSCLC typically must choose between a surgery with superior local control (lobectomy) or one that preserves lung parenchyma (wedge). Recognizing that many patients with cancer have competing mortality risks unrelated to cancer, we investigated whether an established model of predicting life expectancy could be used to identify patients with stage I NSCLC for whom survival after wedge is not different from lobectomy.
A retrospective cohort study using the National Cancer Institute's Surveillance Epidemiology and End Results-Medicare was performed to evaluate survival among treatment-naive patients, diagnosed 2005-2015, who underwent lobectomy or wedge for stage I (≤2 cm tumors) NSCLC. Comorbidity-related life expectancy (CR-LE) was estimated using a standard life-table approach based on comorbid conditions, sex, and age. Cox models and perioperative complications were stratified by 5-year CR-LE.
A total of 4560 patients (median age 74, interquartile range 70-78) were identified. CR-LE was greater than or equal to 5 years for 4016 patients (wedge = 23%). CR-LE was less than 5 years for 544 patients (wedge = 41%). Among patients with CR-LE greater than or equal to 5, wedge resection was associated with higher risk of mortality than lobectomy (hazard ratio: 1.68, 95% confidence interval: 1.52-1.86, < 0.001). For those with CR-LE less than 5, there was no significant difference in mortality risk between lobectomy and wedge (hazard ratio: 1.19, 95% confidence interval: 0.96-1.47; = 0.11). CR-LE less than five patients who underwent a lobectomy had higher 90-day mortality compared with wedge (9% versus 4%, = 0.04).
The survival advantage of lobectomy over wedge for stage I NSCLC seems to dissipate among patients with shorter life expectancy owing to age and comorbidities. Wedge resection may be a reasonable option for patients at high risk of dying from non-cancer-related causes.
早期非小细胞肺癌(NSCLC)患者通常必须在具有更好局部控制效果的手术(肺叶切除术)和保留肺实质的手术(楔形切除术)之间做出选择。鉴于许多癌症患者存在与癌症无关的相互竞争的死亡风险,我们研究了一种既定的预测预期寿命的模型是否可用于识别I期NSCLC患者中楔形切除术后生存率与肺叶切除术后无差异的患者。
利用美国国立癌症研究所的监测、流行病学和最终结果-医疗保险数据库进行了一项回顾性队列研究,以评估2005年至2015年期间初次接受治疗、因I期(肿瘤≤2cm)NSCLC接受肺叶切除术或楔形切除术的患者的生存率。使用基于合并症、性别和年龄的标准生命表方法估计合并症相关预期寿命(CR-LE)。Cox模型和围手术期并发症按5年CR-LE进行分层。
共识别出4560例患者(中位年龄74岁,四分位间距70-78岁)。4016例患者的CR-LE大于或等于5年(楔形切除术=23%)。544例患者的CR-LE小于5年(楔形切除术=41%)。在CR-LE大于或等于5年的患者中,楔形切除术与高于肺叶切除术的死亡风险相关(风险比:1.68,95%置信区间:1.52-1.86,P<0.001)。对于CR-LE小于5年的患者,肺叶切除术和楔形切除术之间的死亡风险无显著差异(风险比:1.19,95%置信区间:0.96-1.47;P=0.11)。与楔形切除术相比,接受肺叶切除术的CR-LE小于5年的患者90天死亡率更高(9%对4%,P=0.04)。
对于I期NSCLC,肺叶切除术相对于楔形切除术的生存优势在因年龄和合并症导致预期寿命较短的患者中似乎消失。对于有死于非癌症相关原因高风险的患者,楔形切除术可能是一个合理的选择。